<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Patients who should undergo evaluation for endometrial hyperplasia or endometrial cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Patients who should undergo evaluation for endometrial hyperplasia or endometrial cancer</h1>
<div class="graphic"><div class="figure"><div class="ttl">Patients who should undergo evaluation for endometrial hyperplasia or endometrial cancer</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single">Abnormal uterine bleeding</td> </tr> <tr> <td> <ul class="decimal_heading"> <li>Postmenopausal patients* – Any uterine bleeding, regardless of volume (including spotting or staining). Pelvic ultrasound to evaluate endometrial thickness is an alternative to endometrial sampling in appropriately selected patients. An endometrial lining &gt;4 mm or an endometrium that is not adequately visualized or shows diffuse or focal heterogeneity should be further evaluated with endometrial sampling.</li> </ul> </td> </tr> <tr> <td> <ul class="decimal_heading"> <li>Age 45 years to menopause – In any patient, bleeding that is frequent (interval between the onset of bleeding episodes is &lt;21 days), heavy, or prolonged (&gt;8 days). In patients who are ovulatory, this includes intermenstrual bleeding.</li> </ul> </td> </tr> <tr> <td> <ul class="decimal_heading"> <li>Younger than 45 years – Any abnormal uterine bleeding in patients with BMI ≥30 kg/m<sup>2</sup>. In patients with BMI &lt;30 kg/m<sup>2</sup>, abnormal uterine bleeding that is persistent and occurs in the setting of one of the following: chronic ovulatory dysfunction, other exposure to estrogen unopposed by progesterone, failed medical management of the bleeding, or patients at high risk of endometrial cancer (eg, Lynch syndrome, Cowden syndrome).</li> </ul> </td> </tr> <tr> <td> <ul class="decimal_heading"> <li>In addition, endometrial neoplasia should be suspected in premenopausal patients who are anovulatory and have prolonged periods of amenorrhea (six or more months).</li> </ul> </td> </tr> <tr> <td class="subtitle1_single">Cervical cytology results</td> </tr> <tr> <td> <ul class="decimal_heading"> <li>Presence of AGC-endometrial.</li> </ul> </td> </tr> <tr> <td> <ul class="decimal_heading"> <li>Presence of AGC-all subcategories other than endometrial – If ≥35 years of age <strong>or</strong> at risk for endometrial cancer (risk factors or symptoms).</li> </ul> </td> </tr> <tr> <td> <ul class="decimal_heading"> <li>Presence of benign-appearing endometrial cells in patients ≥40 years of age who also have abnormal uterine bleeding or risk factors for endometrial cancer.</li> </ul> </td> </tr> <tr> <td class="subtitle1_single">Other indications</td> </tr> <tr> <td> <ul class="decimal_heading"> <li>Monitoring of patients with endometrial pathology (eg, endometrial hyperplasia).</li> </ul> </td> </tr> <tr> <td> <ul class="decimal_heading"> <li>Screening in patients at high risk of endometrial cancer (eg, Lynch syndrome).</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">These recommendations are based on an average age of menopause of 51 years. Evaluation of patients who undergo menopause earlier should be individualized based on gynecologic history and risk of endometrial neoplasia.</div><div class="graphic_footnotes"><p>BMI: body mass index; AGC: atypical glandular cells.</p>
    
    * Postmenopausal patients using cyclic progesterone will have predictable, cyclic, uterine bleeding. Evaluation is different for such patients and is discussed in related UpToDate content.</div><div id="graphicVersion">Graphic 58600 Version 16.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
